|
COMMERCE BUSINESS DAILY ISSUE OF APRIL 6,1995 PSA#1319National Institutes of Health, Division of Procurement, AB-A 6120
Executive Blvd., Room 890, Rockville, MD 20892 66 -- MAGNETIC RESONANCE IMAGING (MRI) SOL 263-95-P(GD)-0032 POC
Donald Wilson, Contract Specialist, (301) 402-2849. 17. The National
Institutes of Health intends to negotiate with Invivo Research INC,
12601 Research PKWY, Orlando, FL 32826 as a sole source under the
authority of 41. U.S.C. 253(c)(1), for a Omnitrak MRI (PMS) Patent
Monitoring System model number 3100 (install), including model numbers
3112-1, 3111-2, 90399, 9050M, 9060M, 9070M, 9238, 9239, 918OT, 9010D,
9010F, 9012, 9013, and 9014. The Magnetic Resonance Imaging (MRI)
monitoring system, shall be as manufactured in accordance with the
functional/performance characteristics herein as follows: The NIH
Laboratory of Diagnostic Radiology Research requires a Magnetic
Resonance Imaging (MRI) monitoring system, to work in conjunction with
the Government owned G.E. Signa 1.5 Telsa Magnet. 1. The system shall
be compatible with and provide cardiac, and respiratory gating, for
the G.E Signa 1.5 Telsa MRI unit. It shall have low and nonferrous
content in filtering and circuitry to permit interference free MRI
scanning, and clear, stable ECG waveforms. It shall be designed to
minimize the risk of burns to patients from radio frequency current
generated by the MR unit. 2. Shall be designed to provide continuous,
accurate monitoring for all patients from neonates to adults during
magnetic resonance imaging. 3. The system components and all
accessories shall be fully compatible and operate as a complete patient
monitoring system both inside and outside the magnet room. 4. The
system shall have the capability of monitoring the following
physiological parameters, ECG, respiration, non- invasive blood
pressure, end-tidal CO2, SpO2 and pulse rate. It shall include a
printer, MR cabling, remote monitor, monitor cart, pulse oximeter, and
end-tidal CO2 analyzer, and pre-installation items. 5. The
non-invasive blood pressure monitor shall have a pressure range of
0-255 torr for adult and pediatric patients, and 0- 210 torr for
neonates, and pulse rate accuracy of 0.2% of full scale. 6. The ECG
amplifier shall allow 4 lead configurations, I, II, AVL, AVR, or AVF
with an accuracy of +0.5%. The recorder shall have dual channel, 50mm/s
display. 7. The pulse oxymeter shall have a pulse rate range of 20-250
bpm, and 0.2% accuracy or greater at 90-100% saturation. 8. The
CO2/N2O module shall measure ranges of 0-76mmHg for CO2 with 3mmHg.
accuracy, and 0-99% for N2O with full scale accuracy of 0.5%. 9. It
shall include installation and testing of all components by factory
trained systems technicians. 10. The system shall have FDA approval and
conform to the Joint Commission on Accreditation of Healthcare
Organization (JCAHO) guidelines for monitoring sedated and anesthetized
patients. It shall have high and low alarms for systolic and diastolic
blood pressure and heart rate. 11. The system shall be capable of both
close and remote monitoring and provide complete patient documentation.
12. The system shall offer preprogrammed and manual options for setup
and configuration. This shall include automatic blood pressure
measurements taken at intervals selectable by the user for adult,
pediatric and neonatal patients. It is the Government's belief that
these requirements can be met by Invivo Research INC. This is not a
formal solicitation. However, concerns that respond to this notice must
furnish concise responses directed specifically to the requirements
mentioned above. Sources demonstrating the capability to accomplish the
above shall supply pertinent information in sufficient detail to
demonstrate that ability to perform. Information furnished shall
include enough material to perform a proper evaluation. Respondents
will not be notified of the evaluation results. See note 22: (0094) Loren Data Corp. http://www.ld.com (SYN# 0374 19950405\66-0001.SOL)
66 - Instruments and Laboratory Equipment Index Page
|
|